SCHEMBL5962230

SCHEMBL5962230

CCOC(=O)c1cn(Cc2ccncc2)c2cnc(Br)cc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
P2RX3 P56373 1/20 0.49
POLB P06746 1/20 0.43
KMT2A Q03164 2/20 0.43
ROCK2 O75116 1/20 0.43
CDK1 P06493 1/20 0.43
PRKACA P17612 1/20 0.43
CDK2 P24941 1/20 0.43
CSNK1D P48730 1/20 0.43
GSK3A P49840 1/20 0.43
CDK5 Q00535 1/20 0.43
PRKCD Q05655 1/20 0.43
ROCK1 Q13464 1/20 0.43
CDC42BPA Q5VT25 1/20 0.43
MARK2 Q7KZI7 1/20 0.43
USP2 O75604 1/20 0.43
MAPK10 P53779 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
THRB P10828 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3692565 0.85 LMNA (0.49) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL5962221 0.85 LMNA (0.67) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL3003393 0.82 LMNA (0.54) LMNAP2RX3POLBKMT2AROCK2
SCHEMBL7057720 0.82 THRB (0.59) LMNAP2RX3POLBKMT2AALDH1A1
SCHEMBL3697710 0.81 LMNA (0.49) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL5962157 0.81 LMNA (0.53) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL5962175 0.81 LMNA (0.53) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL7123296 0.80 P2RX3 (0.55) LMNAP2RX3POLBKMT2AROCK2
SCHEMBL5962176 0.80 LMNA (0.52) LMNAP2RX3POLBKMT2AKDM4E
SCHEMBL5962219 0.78 LMNA (0.50) LMNAPOLBKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US disclosed
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US disclosed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US disclosed
WO-2010136817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 LMNA 2498/4885P2RX3 1664/4885POLB 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.